Senti Biosciences (SNTI) Competitors $1.64 +0.06 (+3.46%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.64 -0.01 (-0.36%) As of 08/22/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNTI vs. SLS, FTLF, MEIP, LXEO, THTX, CLLS, ENTA, KRRO, MOLN, and BHSTShould you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include SELLAS Life Sciences Group (SLS), FitLife Brands (FTLF), MEI Pharma (MEIP), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), Cellectis (CLLS), Enanta Pharmaceuticals (ENTA), Korro Bio (KRRO), Molecular Partners (MOLN), and BioHarvest Sciences (BHST). These companies are all part of the "pharmaceutical products" industry. Senti Biosciences vs. Its Competitors SELLAS Life Sciences Group FitLife Brands MEI Pharma Lexeo Therapeutics Theratechnologies Cellectis Enanta Pharmaceuticals Korro Bio Molecular Partners BioHarvest Sciences SELLAS Life Sciences Group (NASDAQ:SLS) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability. Is SLS or SNTI more profitable? SELLAS Life Sciences Group's return on equity of -132.51% beat Senti Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences GroupN/A -132.51% -92.79% Senti Biosciences N/A -223.98%-76.02% Do insiders and institutionals have more ownership in SLS or SNTI? 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 1.4% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 3.1% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer SLS or SNTI? In the previous week, SELLAS Life Sciences Group had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 4 mentions for SELLAS Life Sciences Group and 2 mentions for Senti Biosciences. SELLAS Life Sciences Group's average media sentiment score of 0.81 beat Senti Biosciences' score of 0.68 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Senti Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, SLS or SNTI? SELLAS Life Sciences Group has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Which has stronger earnings & valuation, SLS or SNTI? SELLAS Life Sciences Group has higher earnings, but lower revenue than Senti Biosciences. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSELLAS Life Sciences Group$1M201.12-$30.88M-$0.32-5.97Senti Biosciences$2.56M16.81-$52.79M-$8.95-0.18 Do analysts rate SLS or SNTI? SELLAS Life Sciences Group presently has a consensus price target of $7.00, indicating a potential upside of 266.49%. Senti Biosciences has a consensus price target of $8.50, indicating a potential upside of 416.72%. Given Senti Biosciences' higher probable upside, analysts clearly believe Senti Biosciences is more favorable than SELLAS Life Sciences Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySELLAS Life Sciences Group and Senti Biosciences tied by winning 7 of the 14 factors compared between the two stocks. Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNTI vs. The Competition Export to ExcelMetricSenti BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.60M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.09%P/E Ratio-0.1820.8831.1026.05Price / Sales16.81356.38436.12105.98Price / CashN/A43.1937.7358.48Price / Book1.758.129.536.61Net Income-$52.79M-$54.72M$3.26B$265.56M7 Day Performance8.22%2.62%2.11%1.98%1 Month Performance-17.34%7.63%5.12%1.33%1 Year Performance-38.62%13.11%31.25%21.15% Senti Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNTISenti Biosciences2.7897 of 5 stars$1.65+3.5%$8.50+416.7%-38.6%$41.60M$2.56M-0.184SLSSELLAS Life Sciences Group2.9108 of 5 stars$1.55+0.3%$7.00+353.1%+45.8%$154.16M$1M-4.0710FTLFFitLife Brands4.1646 of 5 stars$16.33+4.5%$20.50+25.5%+8.0%$153.34M$64.47M19.4420MEIPMEI Pharma1.5017 of 5 stars$4.68-3.2%N/A+58.8%$151.33M$65.30M-0.98100LXEOLexeo Therapeutics2.3756 of 5 stars$4.52+1.9%$17.17+279.5%-59.8%$149.73M$650K-1.3758Analyst RevisionTHTXTheratechnologiesN/A$3.22+0.5%N/A+158.7%$147.83M$85.87M-16.92140News CoverageShort Interest ↓CLLSCellectis3.4335 of 5 stars$2.66+0.2%$4.00+50.7%+22.8%$147.57M$49.22M-3.24290Positive NewsShort Interest ↓ENTAEnanta Pharmaceuticals3.6602 of 5 stars$6.81+4.9%$21.67+218.2%-29.5%$145.64M$67.64M-1.50160KRROKorro Bio1.3805 of 5 stars$15.51+3.1%$102.43+560.4%-54.7%$145.64M$2.27M-1.6470Gap DownMOLNMolecular Partners2.4006 of 5 stars$3.59+3.3%$12.00+234.7%-43.9%$144.76M$5.65M-1.87180News CoverageUpcoming EarningsGap UpBHSTBioHarvest SciencesN/A$8.81-0.1%$13.67+55.1%N/A$144.66M$25.19M-17.62N/AGap Down Related Companies and Tools Related Companies SELLAS Life Sciences Group Alternatives FitLife Brands Alternatives MEI Pharma Alternatives Lexeo Therapeutics Alternatives Theratechnologies Alternatives Cellectis Alternatives Enanta Pharmaceuticals Alternatives Korro Bio Alternatives Molecular Partners Alternatives BioHarvest Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNTI) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access